Literature DB >> 26721800

Humanized hemato-lymphoid system mice.

Alexandre P A Theocharides1, Anthony Rongvaux2, Kristin Fritsch1, Richard A Flavell2, Markus G Manz3.   

Abstract

Over the last decades, incrementally improved xenograft mouse models, supporting the engraftment and development of a human hemato-lymphoid system, have been developed and now represent an important research tool in the field. The most significant contributions made by means of humanized mice are the identification of normal and leukemic hematopoietic stem cells, the characterization of the human hematopoietic hierarchy, and their use as preclinical therapy models for malignant hematopoietic disorders. Successful xenotransplantation depends on three major factors: tolerance by the mouse host, correct spatial location, and appropriately cross-reactive support and interaction factors such as cytokines and major histocompatibility complex molecules. Each of these can be modified. Experimental approaches include the genetic modification of mice to faithfully express human support factors as non-cross-reactive cytokines, to create free niche space, the co-transplantation of human mesenchymal stem cells, the implantation of humanized ossicles or other stroma, and the implantation of human thymic tissue. Besides the source of hematopoietic cells, the conditioning regimen and the route of transplantation also significantly affect human hematopoietic development in vivo. We review here the achievements, most recent developments, and the remaining challenges in the generation of pre-clinically-predictive systems for human hematology and immunology, closely resembling the human situation in a xenogeneic mouse environment. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2016        PMID: 26721800      PMCID: PMC4697887          DOI: 10.3324/haematol.2014.115212

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  110 in total

Review 1.  Biology of hematopoietic stem cells and progenitors: implications for clinical application.

Authors:  Motonari Kondo; Amy J Wagers; Markus G Manz; Susan S Prohaska; David C Scherer; Georg F Beilhack; Judith A Shizuru; Irving L Weissman
Journal:  Annu Rev Immunol       Date:  2002-12-17       Impact factor: 28.527

2.  Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells.

Authors:  Frédéric Mazurier; Monica Doedens; Olga I Gan; John E Dick
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

3.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

4.  Tissue engineered humanized bone supports human hematopoiesis in vivo.

Authors:  Boris M Holzapfel; Dietmar W Hutmacher; Bianca Nowlan; Valerie Barbier; Laure Thibaudeau; Christina Theodoropoulos; John D Hooper; Daniela Loessner; Judith A Clements; Pamela J Russell; Allison R Pettit; Ingrid G Winkler; Jean-Pierre Levesque
Journal:  Biomaterials       Date:  2015-05-19       Impact factor: 12.479

5.  Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.

Authors:  M Feuring-Buske; B Gerhard; J Cashman; R K Humphries; C J Eaves; D E Hogge
Journal:  Leukemia       Date:  2003-04       Impact factor: 11.528

6.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 7.  Xenograft models for normal and malignant stem cells.

Authors:  Susumu Goyama; Mark Wunderlich; James C Mulloy
Journal:  Blood       Date:  2015-03-11       Impact factor: 22.113

8.  NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration.

Authors:  F E Nicolini; J D Cashman; D E Hogge; R K Humphries; C J Eaves
Journal:  Leukemia       Date:  2004-02       Impact factor: 11.528

9.  Prospective isolation of human clonogenic common myeloid progenitors.

Authors:  Markus G Manz; Toshihiro Miyamoto; Koichi Akashi; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-22       Impact factor: 11.205

10.  Nonirradiated NOD,B6.SCID Il2rγ-/- Kit(W41/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells.

Authors:  Brian E McIntosh; Matthew E Brown; Bret M Duffin; John P Maufort; David T Vereide; Igor I Slukvin; James A Thomson
Journal:  Stem Cell Reports       Date:  2015-01-15       Impact factor: 7.765

View more
  75 in total

1.  Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.

Authors:  Renier Myburgh; Jonathan D Kiefer; Norman F Russkamp; Chiara F Magnani; Nicolás Nuñez; Alexander Simonis; Surema Pfister; C Matthias Wilk; Donal McHugh; Juliane Friemel; Antonia M Müller; Burkhard Becher; Christian Münz; Maries van den Broek; Dario Neri; Markus G Manz
Journal:  Leukemia       Date:  2020-05-01       Impact factor: 11.528

Review 2.  Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia.

Authors:  Olivia L Francis; Terry-Ann M Milford; Cornelia Beldiman; Kimberly J Payne
Journal:  J Investig Med       Date:  2016-02-12       Impact factor: 2.895

3.  NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.

Authors:  Emmanuel Griessinger; Michael Andreeff
Journal:  Haematologica       Date:  2018-06       Impact factor: 9.941

4.  Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models.

Authors:  Trisha R Sippel; Stefan Radtke; Tayla M Olsen; Hans-Peter Kiem; Anthony Rongvaux
Journal:  Blood Adv       Date:  2019-02-12

Review 5.  Cancer Stem Cells (CSCs) in melanoma: There's smoke, but is there fire?

Authors:  Constance E Brinckerhoff
Journal:  J Cell Physiol       Date:  2017-03-06       Impact factor: 6.384

Review 6.  Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice.

Authors:  Yoriko Saito; Leonard D Shultz; Fumihiko Ishikawa
Journal:  Trends Immunol       Date:  2020-07-03       Impact factor: 16.687

7.  Versatile humanized niche model enables study of normal and malignant human hematopoiesis.

Authors:  Ander Abarrategi; Katie Foster; Ashley Hamilton; Syed A Mian; Diana Passaro; John Gribben; Ghulam Mufti; Dominique Bonnet
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

Review 8.  Humanized mouse model: a review on preclinical applications for cancer immunotherapy.

Authors:  Ling Yin; Xue-Jing Wang; De-Xi Chen; Xiao-Ni Liu; Xiao-Jun Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 9.  Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.

Authors:  Katrina E Allison; Brenda L Coomber; Byram W Bridle
Journal:  Immunology       Date:  2017-07-10       Impact factor: 7.397

10.  Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy.

Authors:  Drake J Smith; Levina J Lin; Heesung Moon; Alexander T Pham; Xi Wang; Siyuan Liu; Sunjong Ji; Valerie Rezek; Saki Shimizu; Marlene Ruiz; Jennifer Lam; Deanna M Janzen; Sanaz Memarzadeh; Donald B Kohn; Jerome A Zack; Scott G Kitchen; Dong Sung An; Lili Yang
Journal:  Stem Cells Dev       Date:  2016-10-18       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.